Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

The Doctor Who Sees the X-Ray Before the Patient Feels the Pain: Jim Rickards Says the AI Tumor Is Already There — Most People Just Haven't Been Told Yet

View original at globenewswire.com
The Doctor Who Sees the X-Ray Before the Patient Feels the Pain: Jim Rickards Says the AI Tumor Is Already There — Most People Just Haven't Been Told Yet Washington, D.C., April 04, 2026 (GLOBE NEWSWIRE) -- There is a specific kind of dread that comes from learning a threat was already present before any symptoms appea…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The collapse has already started behind the scenes

    60% confidence

  • The company at the center of the AI financial system is showing the same distress signals Lehman showed weeks before its failure

    60% confidence

  • In 2008, warned that financial catastrophe was imminent three weeks before Lehman Brothers collapsed

    60% confidence

  • This is not a prediction, it is an observation - describing what is already happening, visible to anyone with access to the right data points

    60% confidence

  • The CFO of the AI company identified as central failure point has implied publicly that a government bailout may be required

    60% confidence

  • The evidence of a coming AI market collapse is already present in the balance sheets, financing arrangements, insider behavior, and structural fragilities of the AI sector

    60% confidence

  • In January 2020, issued CONTAGION note predicting a pandemic-driven market panic three weeks before stocks suffered the fastest crash in history

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
The Doctor Who Sees the X-Ray Before the Patient Feels the Pain: Jim Rickards Says the AI Tumor Is Already There — Most People Just Haven't Been Told Yet — Source | Via News | ViaNews EU